The maximum number of years that the targeted drugs ivonib/ivitinib can be taken

Ivosidenib/Ivosidenib is a targeted drug mainly used to treat specific types of cancer, especially acute myeloid leukemia (AML) and certain solid tumors. According to clinical research and clinical practice, there is no fixed upper limit for the use time of ivonib, because the length of its treatment often depends on multiple factors, including the patient's specific condition, drug tolerance, individual response, etc.

The duration of use of ivosidenib is usually evaluated under the guidance of a physician. For some patients, targeted therapy may be part of long-term management, especially if the disease is under control. For example, for patients with certain chronic diseases, doctors may recommend continued use of ivonib until the disease is effectively controlled or obvious side effects occur.

The patient's tolerance to ivonib is also one of the key factors in determining the duration of administration. Many patients may experience some side effects during the early stages of using ivonib, such as nausea, loss of appetite, fatigue, etc. These side effects are generally controllable. If the patient tolerates these side effects well and the disease is well controlled, ivonib can be continued for an extended period of time. However, if a patient experiences serious adverse effects or the condition progresses, the doctor may adjust the treatment, including discontinuing the drug.

In addition, the efficacy of ivonib will also affect the duration of its use. Avosidenib has shown promising therapeutic effects in some clinical trials, but responses to the drug may vary among individuals. Some patients may experience complete or partial response while taking the drug, while others may experience no significant improvement. Therefore, continuation of treatment will be based on assessment of efficacy.

While patients are taking ivonib, doctors will perform regular blood tests and imaging tests to evaluate the effectiveness of the treatment and detect potential side effects. These monitoring results will directly affect subsequent treatment decisions, deciding whether to continue, adjust or stop the use of ivonib.